Israel - English - Ministry of Health

novartis israel ltd - pemetrexed as disodium - powder for concentrate for solution for infusion - pemetrexed as disodium 500 mg/vial - pemetrexed - pemetrexed sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

novartis israel ltd - pemetrexed as disodium - powder for concentrate for solution for infusion - pemetrexed as disodium 500 mg/vial - pemetrexed - pemetrexed sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

novartis israel ltd - pemetrexed as disodium - powder for concentrate for solution for infusion - pemetrexed as disodium 100 mg/vial - pemetrexed - pemetrexed sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 100 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

in2health solutions pty ltd - 58884 - self-care monitoring web-based application software - gmdn code 58884 self care monitoring web-based application. this is a web based application (internet based information system) for use on desk top computers or hand held smart devices. the purpose of this application is to improve population health by assessing risk of chronic disease, improving individual health literacy, facilitating self care and consequent chronic disease risk reduction. the system is based on a comprehensive, evidence based algorithms that provide individuals with a chronic disease risk assessment based on modifiable lifestyle and workplace risk factors as well as non modifiable risk factors such as family history. the system then aggregates this data and links individuals at high risk with appropriate pathology, radiology and/or health providers through specialist referrals (care plan). those identified as being at high and moderate risk for any condition will also be provided with an evidence based lifestyle plan and coaching to inspire sustained behaviour change. when used in organisations, the employer is provided with de-identified data on risk factors of their workforce to enable development of targeted programs to modify these. the outcome will be presented as a high moderate or low risk for 14 chronic health conditions. these conditions include ischaemic heart disease, type 2 diabetes, gestational diabetes, chronic renal disease, hypertension, cerebrovascular disease, obstructive sleep apnoea, bowel cancer, breast cancer, melanomatous and non melanomatous skin cancer, lung and prostate cancer, mental health conditions (ptsd, depression and anxiety) and osteoporosis. in summary, this is a risk assessment tool, designed to identify those at risk and reduce their risk prior to them developing chronic health conditions and the subsequent de-identified aggregated data enables employers to support their workforce in doing so through an integrated approach to risk factor reduction.

Australia - English - Department of Health (Therapeutic Goods Administration)

independent dental supplies pty ltd - 31780 - dental material, pit/fissure sealing, polymer based - a resin based material suitable for sealing pits and fissures on teeth.it may be mechanically cured or external energy cured

Australia - English - Department of Health (Therapeutic Goods Administration)

w9 pty ltd - 31780 - dental material, pit/fissure sealing, polymer based - a resin-based material suitable for sealing pits and fissures on teeth. it may be chemically cured or external energy cured.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dermal laboratories ltd - isopropyl myristate; liquid paraffin - cutaneous gel - 150mg/1gram ; 150mg/1gram